Clinical Trial Update: Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety and tolerability of XmAb5574 in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• XmAb5574

Snippet

Sponsor: Xencor, Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 | Status: COMPLETED